Lineage specific biomarkers predict response to FGFR inhibition

Por Loch, David C., Pollock, Pamela M.
Publicado no Cancer Discov (2012)

Prevention of Hypertension in DOCA-Salt Rats by an Inhibitor of Soluble Epoxide Hydrolase

Por Loch, David, Hoey, Andrew, Morisseau, Christophe, Hammock, Bruce O., Brown, Lindsay
Publicado em 2007

p38 MAPK Is an Early Determinant of Promiscuous Smad2/3 Signaling in the Aortas of Fibrillin-1 (Fbn1)-null Mice

Por Carta, Luca, Smaldone, Silvia, Zilberberg, Lior, Loch, David, Dietz, Harry C., Rifkin, Daniel B., Ramirez, Francesco
Publicado em 2009

Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN status

Por Byron, Sara A, Loch, David C, Wellens, Candice L, Wortmann, Andreas, Wu, Jiayi, Wang, John, Nomoto, Kenichi, Pollock, Pamela M
Publicado em 2012

The N550K/H Mutations in FGFR2 Confer Differential Resistance to PD173074, Dovitinib, and Ponatinib ATP-Competitive Inhibitors

Por Byron, Sara A, Chen, Huaibin, Wortmann, Andreas, Loch, David, Gartside, Michael G, Dehkhoda, Farhad, Blais, Steven P, Neubert, Thomas A, Mohammadi, Moosa, Pollock, Pamela M
Publicado em 2013

Circulating TGFβ in Marfan's Syndrome

Por Matt, Peter, Schoenhoff, Florian, Habashi, Jennifer, Holm, Tammy, Van Erp, Christel, Loch, David, Carlson, Olga D., Griswold, Benjamin F., Fu, Qin, De Backer, Julie, Loeys, Bart, Huso, David, McDonnell, Nazli B., Van Eyk, Jennifer E., Dietz, Harry C.
Publicado em 2009

Angiotensin II–dependent TGF-β signaling contributes to Loeys-Dietz syndrome vascular pathogenesis

Por Gallo, Elena M., Loch, David C., Habashi, Jennifer P., Calderon, Juan F., Chen, Yichun, Bedja, Djahida, van Erp, Christel, Gerber, Elizabeth E., Parker, Sarah J., Sauls, Kimberly, Judge, Daniel P., Cooke, Sara K., Lindsay, Mark E., Rouf, Rosanne, Myers, Loretha, ap Rhys, Colette M., Kent, Kathleen C., Norris, Russell A., Huso, David L., Dietz, Harry C.
Publicado em 2013